BioSpace News Archive

PTC Therapeutics, Inc. announced that on April 17, 2020 it approved non-statutory stock options to purchase an aggregate of 151,850 shares of its common stock and 6,260 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 49 new employees.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 29, at 4:15 p.m. ET to discuss first quarter 2020 financial results and provide a general business update.

Chiasma, Inc., a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases, announced the appointment of Anand Varadan as Executive Vice President, Chief Commercial Officer.

Predictive Oncology (NASDAQ: POAI) today announced that it has entered into an Exchange Agreement relating to a $2.1 million promissory note of the Company with Dr. Carl Schwartz, the company’s Chief Executive Officer.

Incyte (Nasdaq:INCY) today announced that data from the Phase 3 REACH2 study have been published in The New England Journal of Medicine demonstrating that ruxolitinib (Jakafi®) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy (BAT).

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has applied for an Emergency Use Authorization (EUA) for the Lyra® Direct SARS-CoV-2 Assay from the Food and Drug Administration (FDA) to allow direct sample processing.

Lexicon Pharmaceuticals, Inc. will release its first quarter 2020 financial results on Monday, April 27, 2020 before market opens.

Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2020. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards..

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

Samsung Biologics and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018.